Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$44.18 ▲ +0.93
(+2.15%)
MKT CAP: $5.38B • VOL: 1.29M
52W L $27 52W H $62
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$37
MEDIAN
$49
MEAN
$50
HIGH
$60
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE SRRK TAPE
SRRK // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $53.46 | $50.81 | 2025-02-14 | $40.20 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $55.67 | $52.13 | 2025-02-06 | $41.53 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $50.37 | $48.60 | 2025-01-29 | $42.41 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $45.06 | — | 2025-01-17 | $43.30 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $38.88 | $41.97 | 2025-01-09 | $39.32 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $52.57 | $45.95 | 2024-12-18 | $38.44 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $42.85 | $44.62 | 2024-12-04 | $41.09 | -4.3% | 48% | C |